Loading clinical trials...

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | Clinical Trials | Clareo Health

UNKNOWNPhase 2NCT04405375

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphom...

Lead sponsor: Beijing Tongren Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITING

A Registry for People With T-cell Lymphoma

NCT05978141 · T-cell Lymphoma, NK-Cell Lymphoma, and more

COMPLETEDPhase 2

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451 · Peripheral T Cell Lymphoma, PTCL, and more

TERMINATEDPhase 1/2

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

NCT04509466 · Extranodal NK/T-cell Lymphoma, Nasal Type

UNKNOWNPhase 3

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

NCT02631239 · Extranodal NK/T-cell Lymphoma, Nasal Type

UNKNOWNPhase 2

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

NCT04676789 · Extranodal NK/T-cell Lymphoma, Nasal Type

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 28, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment29

Start dateMar 2020

Last updatedMay 28, 2020

Condition

Extranodal NK/T-cell Lymphoma, Nasal Type

Locations shown

Beijing Tongren Hospital

Beijing

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 28, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions